Beta Drugs (NSE:BETA) Tariff Resilience Score: 0/10 (As of Jul. 11, 2026)


NSE:BETA Beta Drugs Ltd NSE:BETA
91 GF Score
Price ₹2,366.80
GF Value ₹1,975.60
Valuation Modestly Overvalued
! 6 Warning Signs
View Full Analysis

What is Beta Drugs Tariff Resilience Score?

Beta Drugs has the Tariff Resilience Score of 0, which implies that the company might have .

Beta Drugs has

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Beta Drugs might have .

Beta Drugs  (NSE:BETA) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Beta Drugs Tariff Resilience Score Related Terms

NSE:BETA
91GF Score
Beta Drugs Ltd NSE:BETA
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Beta Drugs (NSE:BETA) Overvalued in 2026?

Based on GuruFocus' analysis, Beta Drugs stock appears to be overvalued. The current stock price of ₹2,366.80 is trading 19.8% above its estimated GF Value™ of ₹1,975.60. GuruFocus considers Beta Drugs to be Modestly Overvalued.

Key valuation signals for NSE:BETA:

  • Tariff Resilience Score: 0
  • GF Value™: ₹1,975.60 vs. price of ₹2,366.80 (19.8% above fair value)
  • GF Score™: 91/100 with 6 warning signs

No single metric tells the full story. See the NSE:BETA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Beta Drugs Business Description

Address SCO-184, First Floor, Sector-5, Panchkula, HR, IND, 134114
Beta Drugs Ltd operates in the pharmaceutical industry. The company manufactures and sells Oncology products in the form of tablets, capsules, oral formulations, and injections. It sells the products in India and also exports them to other countries, of which key revenue is derived from the sales made in India.
91GF Score

Get the complete analysis for NSE:BETA

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹2,366.80
Price
₹1,975.60
GF Value